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Selective serotonin reuptake inhibitor use
and breast cancer survival: a population-
based cohort study
John Busby1* , Ken Mills2, Shu-Dong Zhang2,3, Fabio Giuseppe Liberante2 and Chris R. Cardwell1
Abstract
Background: Nearly 50% of breast cancer patients suffer from depression or anxiety. Selective serotonin reuptake
inhibitors (SSRIs), the first-line pharmacological treatment for depression, have been implicated in breast cancer
development through increased prolactin levels and tamoxifen metabolism inhibition. Previous studies of breast cancer
progression have focused on tamoxifen users, or have been limited by their small sample size and methodology.
Therefore, we used UK population-based data to more robustly investigate the association between SSRI use and
cancer-specific mortality.
Methods: A cohort of patients with newly-diagnosed breast cancer between 1998 and 2012 was selected from
English cancer registries and linked to prescription records from the Clinical Practice Research Datalink, and to
death records from the Office for National Statistics. We used Cox regression models to calculate hazard ratios
(HRs) comparing mortality between post-diagnostic SSRI users and non-users (using time-dependant covariates),
after adjusting for demographics, comorbidities and pre-diagnosis use of hormone replacement therapy or oral
contraceptives. We conducted several additional analyses to assess causality.
Results: Our cohort included 23,669 breast cancer patients, of which 2672 used SSRIs and 3053 died due to their breast
cancer during follow-up. After adjustment, SSRI users had higher breast cancer-specific mortality than non-users (HR = 1.
27; 95% confidence interval (CI) 1.16, 1.40). However, this association was attenuated when restricting to patients with a
prior history of depression (HR = 1.14; 95% CI 0.98, 1.33), and when comparing to users of other antidepressant
medications (HR = 1.06; 95% CI 0.93, 1.20). There was some evidence of higher mortality among long-term SSRI
users, even when restricting to patients with prior depression (HR = 1.54; 95% CI 1.03, 2.29).
Conclusions: In this large breast cancer cohort, SSRI use was associated with a 27% increase in breast cancer
mortality. The cause of this is unknown; however, confounding by indication seems likely as it was largely attenuated
when restricting to patients with prior depression, or when comparing SSRIs to other antidepressant medications.
Clinicians should not be unduly concerned when prescribing SSRIs to breast cancer patients, but the increase in
mortality among long-term SSRI users warrants further investigation.
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Background
Breast cancer is the second most common cancer in the
world, with 1.7 million new cases diagnosed annually [1,
2]. In England, around 15% of patients die due to the
disease within 5 years [3]. Patients also suffer markedly
reduced quality of life, and substantially higher health-
care costs during treatment and recovery [4–7]. Breast
cancer patients are highly susceptible to mental health
problems with nearly 50% suffering depression or anx-
iety [8], and 10–20% experiencing a major depressive
episode after diagnosis [9, 10].
Selective serotonin reuptake inhibitors (SSRIs) are a
group of antidepressant medications recommended for
moderate/severe depression and treatment-resistant mild
depression [11]. In England, 36 million prescriptions
were dispensed during 2016, representing a 6% rise on
the previous year [12]. Increasing SSRI prescriptions
have also been observed in several other countries in-
cluding the USA, Denmark and Spain [13, 14]. SSRIs are
widely used among breast cancer patients, mainly to
treat depression, but also to control hot flushes [15, 16].
Despite their widespread use, there have long been
concerns that SSRIs may promote breast cancer by in-
creasing prolactin levels [17–19], an accepted risk factor
for tumour progression [20–22]. More recently, SSRIs
have been shown to increase the rate of brain metastases
in breast cancer mouse models, by altering the perme-
ability of the blood–brain barrier [23]. SSRIs may also
affect cancer outcomes by interfering with tamoxifen
metabolism through inhibition of the CYP2D6 enzyme
[24, 25]. In humans, several studies have investigated the
association between SSRIs and breast cancer risk,
although these have reached inconsistent conclusions
[26–28]. Studies of breast cancer progression are rarer,
and have generally focused on patients treated with tam-
oxifen [29, 30]. Only three studies have considered a
broader population of breast cancer patients, and these
were limited by their small size and/or other methodo-
logical weaknesses (e.g. self-reported medication use)
[31–33]. Consequently, we used routine data from the
UK to more robustly assess the association between
SSRI use and mortality among a population-based
cohort of breast cancer patients.
Methods
Data sources
Our study used data from the English National Cancer
Data Repository (NCDR), linked to GP records from the
UK Clinical Practice Research Datalink (CPRD),
deprivation indices from census information and death
registration data from the Office for National Statistics
(ONS). The NCDR holds UK-wide data from English
cancer registries compiled from general practices, NHS
and private hospitals, and death certificates [34]. It
contains detailed information about the patient’s cancer,
including diagnosis year, stage, histologic grade, tumour
histology and treatment (surgery, chemotherapy and
radiotherapy). The CPRD contains computerised med-
ical records from 674 general practices (approximately
7% of the UK population) which are audited for data
completeness and quality [35]. Practices meeting a pre-
defined quality threshold are deemed ‘up to research
standard’ and included in future extracts. Data recorded
within the CPRD include patient demographics, clinical
diagnoses (using Read codes) and prescription medica-
tion use. Previous research has found CPRD prescription
and clinical information to be of high quality [35–37].
ONS death-registration data provide details on the date
and cause(s) of death.
Study design and population
We used the NCDR to identify a cohort of patients with
newly-diagnosed breast cancer (ICD code C50) between
1998 and 2012. Cohort members with a previous record
of cancer were identified and excluded from the analysis
using a list of cancer Read codes modified for use in the
CPRD [38]. Patients were excluded if they were diag-
nosed: (a) before they were registered with a CPRD prac-
tice, (b) before their practice was deemed up to research
standard, (c) after they left a CPRD practice or (d) after
data were last collected from their practice by the CPRD.
A small number of patients were recorded within the
NCDR more than once; when this occurred we used
their first record. Patients with stage zero breast cancer
(ductal carcinoma in situ) were also excluded.
Deaths were identified from ONS records, and breast
cancer-specific deaths were defined as those with a pri-
mary cause of breast cancer (ICD code C50). Patients
who died within the first year of the study were excluded
as it is unlikely that these could be influenced by post-
diagnostic medication use, therefore the follow-up
period started from 1 year after diagnosis. The end of
follow-up was the earliest date of death, end of registra-
tion with the practice, last collection of data from the
practice or end of death record follow-up.
Definition of exposure
We used the British National Formulary to compile a list
of proprietary and generic medication names for SSRIs
(Additional file 1: Appendix 1). We added a lag of
12 months to SSRI use as these medications are unlikely
to have an immediate effect on breast cancer progres-
sion, and to prevent reverse causation [39, 40]. A dia-
gram illustrating our design is shown in Additional file
1: Appendix 2. We defined patients as users if they had
at least one prescription during the exposure period. To
enable the testing of dose–response relationships we
extracted data on the medication prescribed, number of
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packs/tablets and medication strength, and calculated a
defined daily dose (DDD) for each prescription. The
DDD system is a validated measure of drug consumption
maintained by the World Health Organisation [41]. A
single DDD is the average maintenance dose per day of
a drug used for its main indication in adults (e.g. depres-
sion for SSRIs). There was insufficient information to
calculate DDDs for 0.1% of prescriptions, and implaus-
ible values were recorded in a further 0.7%. In these
cases we assumed the most common DDD based on
other prescriptions with complete information. We
calculated a running DDD total for each patient and
identified the day when patients received their first (first
use), 365th (1-year use), 1095th (3-year use) and 1825th
(5-year use) DDD.
Covariates
Patients’ age, smoking, alcohol and obesity (BMI > 30) data
were determined from the closest GP record before breast
cancer diagnosis (values more than 10 years before
diagnoses were discarded). We used GP records to
identify pre-diagnosis comorbidities (cerebrovascular dis-
ease, chronic pulmonary disease, congestive heart disease,
diabetes, liver disease, myocardial infarction, peptic ulcer
disease, peripheral vascular disease, renal disease) using a
list of Read codes modified for use in the CPRD [38]. We
also identified post-cancer diagnosis records of hot flushes
(Read codes 1657, 1662, 1662.12, 2223, K5A2000,
K5A2011, R008100, R008400) as these have been associ-
ated previously with breast cancer outcomes [42], and
SSRIs are sometimes used for this indication [15].
Deprivation data were available from census information
and based on the 2010 Index of Multiple Deprivation
(IMD) score of the patient’s postcode. We used CPRD
prescription records to identify patients who received
hormone therapy treatment (tamoxifen or aromatase
inhibitors) after diagnosis, and those who had used oral
contraceptives or hormone replacement therapy (HRT)
prior to diagnosis, as these have been shown previously to
influence breast cancer development [43, 44].
Statistical analysis
We calculated descriptive statistics and compared the
demographic and clinical characteristics of the SSRI
users and non-users. We used time-dependent Cox
regression models to calculate hazard ratios (HRs) com-
paring breast cancer-specific death between SSRI users
and non-users. In our primary analysis we included SSRI
use as a time-varying covariate to avoid immortal time
bias [45]. Therefore patients were initially included
within the analysis as non-users until 12 months after
their first use (due to the exposure lag), after which they
were included as users. Our primary analysis adjusted
for age at diagnosis, year of diagnosis, deprivation
quintile, comorbidities (separate terms for each), hot
flushes, prior use of HRT or oral contraceptives, and
treatment within 6 months of diagnosis (separate terms
for surgery, chemotherapy, radiotherapy, tamoxifen, aro-
matase inhibitors). We repeated our analysis by the
number of DDDs prescribed (e.g. patients were included
in the 1–364 DDD group until 12 months after they
received their 365th DDD), and for each commonly
prescribed SSRI medication (≥ 2% use in cohort).
Sensitivity and subgroup analyses
We conducted sensitivity analysis for all-cause mortality,
and for cause-specific mortality where deaths with a
secondary cause of breast cancer were included. We also
conducted sensitivity analysis with a lag period of
6 months (patients followed-up from 6 months after diag-
nosis) and 2 years (patients followed-up from 2 years after
diagnosis). We performed two simplified analyses which
controlled for immortal time bias without requiring time-
varying covariates [45]. Firstly, we based SSRI use on the
year after diagnosis. Secondly, we based SSRI use on the
year prior to diagnosis, and followed-up patients from the
date of diagnosis. Diagrams illustrating the design of our
sensitivity analyses which vary the exposure lag and/or
period are given in Additional file 1: Appendix 2. We con-
ducted a separate analysis stratified by tamoxifen use as
previous studies have indicated that SSRIs can interfere
with tamoxifen metabolism [29]. Patients were split into
tamoxifen non-users, users and adherent users (defined as
being prescribed at least 150 DDD in the 6 months after
cancer diagnosis).
To ensure that confounding by indication was not
driving our results we conducted two further sensitivity
analysis restricted to patients with more similar diagno-
ses. First, we restricted our analysis to patients with a
diagnosis of depression (using Read codes from previous
work [46]) or record of antidepressant prescription
(SSRIs, tricyclic antidepressants, monoamine-oxidase
inhibitors, agomelatine, duloxetine, flupentixol, mirtaza-
pine, reboxetine, venlafaxine, vortioxetine), in the year
prior to breast cancer diagnosis. Second, we compared
patients who received SSRIs to those who received a dif-
ferent antidepressant medication after diagnosis (using a
time-varying covariate), as the use of an active compari-
son can overcome several common pharmacoepidemio-
logical biases [47]. Similarly, we conducted negative
control analyses for tricyclic antidepressants and venla-
faxine to identify confounding [48], as they have a much
weaker effect on prolactin levels [49] and do not interact
with tamoxifen metabolism [50, 51] but have similar
indications to SSRIs.
We performed additional sensitivity analysis adjusting
for tumour prognostic features (stage, grade) and patient
lifestyle factors (smoking, alcohol consumption, obesity)
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using complete-case and multiple imputation with
chained equations (MICE). The MICE imputation used
ordered logit models with age, deprivation, death indicator
and the baseline hazard function as covariates [52]. Briefly,
MICE is a simulation-based approach for handling miss-
ing data which leads to valid statistical inferences under
certain circumstances [53]. Lastly we repeated our analysis
but omitted ‘previous hot flush diagnosis’ from the model.
Results
Cohort description
We identified 27,008 breast cancer cases with no prior can-
cer diagnosis registered at CPRD practices. We excluded
3339 patients from the analysis as they had less than
12 months follow-up (n = 3189), stage zero cancer (n =
135) or a duplicate record in the NCDR (n = 15), leaving
23,669 patients for analysis. Median follow-up was 5.5 years
(maximum 17.8 years). SSRI users were more likely to be
younger, from a deprived area, have comorbidities, have
previously received hormone replacement therapy or oral
contraceptives, be treated with chemotherapy and be
current smokers (Table 1).
Association between antidepressant use and survival
SSRI users were at a higher risk of breast cancer death
than SSRI non-users (adjusted HR = 1.27; 95% CI 1.16,
1.40; Table 2) after adjustment for demographics,
comorbidities and pre-diagnosis use of hormone replace-
ment therapy or oral contraceptives. Although there was
no evidence of a strong dose–response relationship, as
patients receiving between 1 and 1095 DDDs had similar
mortality, those receiving more than 1095 DDDs were at
substantially greater risk of death (adjusted HR = 1.54;
95% CI 1.15, 2.07) than non-users. We found higher
HRs of between 1.24 and 1.28 for citalopram, fluoxetine
and paroxetine compared to sertraline (adjusted HR =
0.95; 95% CI 0.73, 1.23; Additional file 1: Appendix 3).
We also found higher breast cancer mortality among
users of tricyclic antidepressants (adjusted HR = 1.30;
95% CI 1.18, 1.43; Table 2) when compared to tricyclic
antidepressant non-users and venlafaxine (adjusted HR
= 1.30; 95% CI 1.04, 1.61) when compared to venlafaxine
non-users, but there was no clear dose–response rela-
tionship. The association between antidepressant use
and breast cancer-specific mortality was attenuated
substantially when restricting to patients with a prior
diagnosis of depression (adjusted HR = 1.14; 95% CI
0.98, 1.33), although mortality remained much higher
among long-term (> 1095 DDD) SSRI users when com-
pared to SSRI non-users. HRs were also attenuated for
tricyclic antidepressants (adjusted HR = 1.07; 95% CI
0.92, 1.25) and venlafaxine (adjusted HR = 1.03; 95% CI
0.76, 1.40), with no apparent dose–response relationship.
Sensitivity and subgroup analyses
Our results were similar in the simpler analyses basing
SSRI use on the first year after diagnosis or the year prior
to diagnosis (Table 3). They were robust to changes in the
exposure lag period from 6 months to 2 years, when
expanding our breast cancer-specific death definition to
include secondary causes, when omitting ‘previous hot
flush diagnosis’ from the case-mix adjustment, for all-
cause mortality, and did not change appreciably when
adjusting for tumour prognostic features (i.e. stage, grade)
or patient lifestyle factors (i.e. smoking, alcohol, obesity)
using complete case or multiple imputation methods.
There were small differences in the association between
SSRI and cancer-specific mortality in tamoxifen users (ad-
justed HR = 1.36; 95% CI 1.15, 1.61), adherent tamoxifen
users (adjusted HR = 1.30; 95% CI 1.03, 1.65) or tamoxifen
non-users (adjusted HR = 1.25; 95% CI 1.11, 1.41). The as-
sociation between SSRI use and breast cancer mortality
was attenuated substantially when comparing to patients
receiving a different antidepressant medication (adjusted
HR = 1.06; 95% CI 0.93, 1.20).
Discussion
Summary of main findings
In this large, population-based cohort of newly-diagnosed
breast cancer patients, we found that use of any SSRI was
associated with a 27% increase in the risk of breast cancer
mortality, and use for 3 years of more was associated with
a 54% increase in mortality, after adjustment for patient
demographics, comorbidities and pre-diagnosis use of
hormone replacement therapy or oral contraceptives.
These findings seem likely to reflect confounding by
indication because the association was similar to those
observed for other antidepressant medications, and was
largely attenuated in additional analysis restricting to
patients with a prior history of depression. However, add-
itional studies are needed to further investigate the in-
crease in mortality observed among long-term SSRI users.
Strengths and weaknesses
Our study is based on a high-quality [35] population-
based cohort of 23,669 patients with registry-confirmed
breast cancer, and is nearly six times larger than previous
work [31]. Patients included in the study had a long
follow-up period after diagnosis of up to 17 years, which
should allow any clinically important effect of SSRIs on
breast cancer progression to become apparent. Linkage to
ONS death registration data allowed robust verification of
death, and facilitated a breast cancer-specific analysis,
which should be more sensitive to small changes in
disease-specific mortality and less susceptible to
confounding by indication than all-cause deaths [40, 54].
Although some misclassification of death cause is possible,
studies have shown this is likely to have a limited impact
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Table 1 Patient characteristics by SSRI use
All patients SSRI use
Non-user User
Number of patients 23,669 18,885 4784
Year of diagnosis
1998–2002 5738 (24.2%) 4491 (23.8%) 1247 (26.1%)
2003–2007 8776 (37.1%) 6911 (36.6%) 1865 (39.0%)
2008–2012 9155 (38.7%) 7483 (39.6%) 1672 (34.9%)
Mean age at diagnosis (SD) 61.9 (14.0) 62.6 (13.9) 58.9 (13.9)
0–49 4774 (20.2%) 3479 (18.4%) 1295 (27.1%)
50–59 5913 (25.0%) 4590 (24.3%) 1323 (27.7%)
60–69 5955 (25.2%) 4903 (26.0%) 1052 (22.0%)
70–79 4037 (17.1%) 3357 (17.8%) 680 (14.2%)
Deprivation quintile
1 (least deprived) 6026 (25.5%) 4923 (26.1%) 1103 (23.1%)
2 6087 (25.7%) 4923 (26.1%) 1164 (24.3%)
3 4873 (20.6%) 3875 (20.5%) 998 (20.9%)
4 3941 (16.7%) 3072 (16.3%) 869 (18.2%)
5 (most deprived) 2733 (11.6%) 2084 (11.0%) 649 (13.6%)
Missing (n) 9 8 1
Comorbidities
Chronic pulmonary disease 2716 (11.5%) 2033 (10.8%) 683 (14.3%)
Diabetes 1456 (6.2%) 1141 (6.0%) 315 (6.6%)
Renal disease 1076 (4.5%) 914 (4.8%) 162 (3.4%)
Cerebrovascular disease 650 (2.7%) 498 (2.6%) 152 (3.2%)
Congestive heart disease 345 (1.5%) 287 (1.5%) 58 (1.2%)
Peripheral vascular disease 264 (1.1%) 211 (1.1%) 53 (1.1%)
Myocardial infarction 250 (1.1%) 199 (1.1%) 51 (1.1%)
Peptic ulcer disease 238 (1.0%) 179 (0.9%) 59 (1.2%)
Liver disease 45 (0.2%) 35 (0.2%) 10 (0.2%)
Hot flushes 1693 (7.2%) 1024 (5.4%) 669 (14.0%)
Pre-diagnosis confounder medication use
Hormone replacement therapy 7002 (29.6%) 5233 (27.7%) 1769 (37.0%)
Oral contraceptive 6009 (25.4%) 4454 (23.6%) 1555 (32.5%)
Treatment
Surgery 19,218 (81.2%) 15,212 (80.6%) 4006 (83.7%)
Tamoxifen 10,051 (42.5%) 8006 (42.4%) 2045 (42.7%)
Radiotherapy 8320 (35.2%) 6683 (35.4%) 1637 (34.2%)
Chemotherapy 6774 (28.6%) 5213 (27.6%) 1561 (32.6%)
Aromatase inhibitors 4975 (21.0%) 4094 (21.7%) 881 (18.4%)
Grade
1 3780 (17.9%) 2988 (17.8%) 792 (18.5%)
2 10,282 (48.7%) 8210 (48.8%) 2072 (48.3%)
3 7039 (33.3%) 5616 (33.4%) 1423 (33.2%)
4 19 (0.1%) 18 (0.1%) 1 (0.0%)
Missing (n) 2549 2053 496
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on our estimates (as there is no obvious mechanism for
differential misclassification) [55] and our results were
similar when including deaths where breast cancer was a
secondary cause. We used prescribing data collected as
part of routine clinical care which accurately reflects GP
prescribing practices and negates the risk of recall bias.
These data also included detailed information on the type
of SSRI, and the strength, quantity and timing of prescrip-
tion, which allowed us to investigate dose–response rela-
tionships and conduct separate analysis for specific
medications. SSRIs are not available over-the-counter in
the UK, which negates exposure misclassification due to
over-the-counter use; however, SSRI prescriptions origin-
ating from secondary care are not captured within the
CPRD.
Our study had several potential weaknesses. It is ob-
servational and hence open to confounding. Although
we have adjusted for several of the key determinants of
breast cancer progression (e.g. age, comorbidities and
treatment), some other risk factors, including ethnicity
and nutrition, were not available within our dataset [56,
57]. Furthermore, tumour stage and grade were missing
for a large proportion of our cohort. Reassuringly, our
findings were little altered when using multiple
imputation to adjust for these factors. We do not know
whether patients adhered to their SSRI medications;
however, our main conclusions were similar when
restricting our analysis to patients who received multiple
prescriptions (e.g. > 1825 DDDs), where non-compliance
is less of a concern. Lastly, we had limited data on hor-
mone receptor status, although adjusting for tamoxifen
and aromatase inhibitor use as proxy measures will limit
the effect of this potential weakness.
Comparison with previous research
We are aware of three previous studies, all based in the
USA, which explored the impact of SSRI use on breast
cancer patients regardless of their use of tamoxifen. The
first study found that SSRI users had similar breast cancer
mortality (adjusted HR = 1.0; 95% CI 0.4, 2.5) to non-
users; however, as it was limited to only 1306 patients and
46 breast cancer deaths, it did not have sufficient statis-
tical power to identify clinically meaningful differences be-
tween exposure groups [33]. The second study found
higher breast cancer mortality among SSRI users (adjusted
HR = 1.40; 95% CI 0.51, 2.79), which was consistent with
our findings of a 27% increase. This study was also limited
by its small sample size (n = 3058), reliance on self-
Table 1 Patient characteristics by SSRI use (Continued)
All patients SSRI use
Non-user User
Stage
1 4791 (49.0%) 3812 (48.8%) 979 (49.7%)
2 3936 (40.2%) 3127 (40.0%) 809 (41.1%)
3 748 (7.6%) 623 (8.0%) 125 (6.4%)
4 309 (3.2%) 254 (3.2%) 55 (2.8%)
Missing (n) 13,885 11,069 2816
Smoking
No 12,975 (61.3%) 10,653 (63.4%) 2328 (53.2%)
Ex 4677 (22.1%) 3696 (22.0%) 976 (22.3%)
Yes 3526 (16.6%) 2457 (14.6%) 1068 (24.4%)
Missing (n) 2491 2079 412
Alcohol
No 3406 (19.7%) 2711 (19.7%) 697 (19.5%)
Ex 347 (2.0%) 252 (1.8%) 95 (2.7%)
Yes 13,577 (78.3%) 10,788 (78.5%) 2787 (77.9%)
Missing (n) 6339 5134 1205
Obesity
Normal 7723 (41.0%) 6178 (41.5%) 1548 (39.3%)
Overweight 6326 (33.6%) 4999 (33.6%) 1325 (33.6%)
Obese 4776 (25.4%) 3707 (24.9%) 1068 (27.1%)
Missing (n) 4844 4001 843
Data presented as n (%) unless otherwise indicated
SSRI selective serotonin reuptake inhibitor, SD standard deviation
Busby et al. Breast Cancer Research  (2018) 20:4 Page 6 of 10
reported questionnaires for medication use, poor response
rate (36.2%) and inability to test dose–response relation-
ships [32].
The third and most recent study, which used elec-
tronic prescribing records to determine SSRI use, death
registries to identify cancer-specific deaths and robust
case-mix adjustment for important prognostic factors
(including stage), reported higher risk of breast cancer
mortality among SSRI users (adjusted HR = 1.14; 95% CI
0.88, 1.48), consistent with our results. However, this
study did not investigate dose–response relationships,
had limited generalisability (due to its restriction to a
single health insurance plan) and included substantially
fewer patients than our study (n = 4216) [31]. Our ana-
lysis improves on previous work by using a large
population-based dataset, with robust outcome and ex-
posure assessment, to investigate breast cancer mortality
by level of SSRI use. Our finding of higher mortality
among long-term SSRI users, even after restricting to
those with a prior diagnosis depression, is particularly
novel and has not been explored previously.
Several studies have investigated SSRI use among tam-
oxifen users. One review concluded that SSRIs substan-
tially inhibited the metabolism of tamoxifen [50], although
Table 2 Association between antidepressant use and breast cancer mortality
All patients (N = 23,669) Prior depression (N = 5417)a
n Person-years Deaths Unadjusted HR
(95% CI)
Adjusted HRb
(95% CI)
n Person-years Deaths Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
All SSRIs combined
Never 18,885 105,433 2539 Reference Reference 2861 15,659 435 Reference Reference
Ever 4784 20,722 514 1.17 (1.07, 1.29) 1.27 (1.16, 1.40) 2556 11,216 294 1.09 (0.93, 1.26) 1.14 (0.98, 1.33)
1–364
DDDs
2502 12,100 321 1.19 (1.06, 1.34) 1.28 (1.14, 1.44) 1055 5357 160 1.10 (0.92, 1.32) 1.15 (0.96, 1.38)
365–1094
DDDs
1176 4992 109 1.02 (0.84, 1.24) 1.12 (0.93, 1.36) 701 3167 68 0.87 (0.67, 1.13) 0.91 (0.70, 1.19)
1095–1824
DDDs
487 1847 47 1.37 (1.03, 1.84) 1.54 (1.15, 2.07) 333 1285 37 1.46 (1.04, 2.07) 1.58 (1.12, 2.24)
1825+
DDDs
619 1782 37 1.32 (0.95, 1.84) 1.53 (1.10, 2.13) 467 1407 29 1.37 (0.92, 2.03) 1.54 (1.03, 2.29)
Tricyclic antidepressants
Never 18,734 104,636 2505 Reference Reference 3140 16,608 463 Reference Reference
Ever 4935 21,519 548 1.25 (1.14, 1.38) 1.30 (1.18, 1.43) 2277 10,267 266 1.08 (0.92, 1.25) 1.07 (0.92, 1.25)
1–364
DDDs
4041 17,989 464 1.24 (1.12, 1.37) 1.29 (1.17, 1.43) 1583 7509 203 1.05 (0.89, 1.24) 1.06 (0.89, 1.25)
365–1094
DDDs
574 2416 70 1.50 (1.18, 1.91) 1.51 (1.19, 1.92) 431 1865 53 1.32 (0.99, 1.77) 1.27 (0.94, 1.70)
1095–1824
DDDs
170 661 9 0.82 (0.43, 1.58) 0.94 (0.49, 1.80) 140 521 6 0.65 (0.29, 1.46) 0.68 (0.30, 1.52)
1825+
DDDs
150 454 5 0.75 (0.31, 1.81) 0.87 (0.36, 2.10) 123 372 4 0.71 (0.26, 1.92) 0.77 (0.29, 2.08)
Venlafaxine
Never 22,826 122,227 2968 Reference Reference 4976 24,830 684 Reference Reference
Ever 843 3928 85 1.02 (0.82, 1.26) 1.30 (1.04, 1.61) 441 2046 45 0.94 (0.69, 1.27) 1.03 (0.76, 1.40)
1–364
DDDs
522 2531 66 1.19 (0.93, 1.51) 1.64 (1.28, 2.10) 214 1068 29 1.08 (0.74, 1.56) 1.32 (0.91, 1.92)
365–1094
DDDs
161 861 11 0.60 (0.33, 1.09) 0.67 (0.37, 1.21) 105 557 9 0.67 (0.35, 1.29) 0.66 (0.34, 1.28)
1095–1824
DDDs
68 293 2 0.36 (0.09, 1.43) 0.36 (0.09, 1.45) 47 227 1 0.22 (0.03, 1.57) 0.20 (0.03, 1.42)
1825+
DDDs
92 243 6 1.55 (0.70, 3.46) 1.76 (0.79, 3.94) 75 194 6 1.94 (0.86, 4.37) 2.05 (0.91, 4.63)
HR hazard ratio, CI confidence interval, SSRI selective serotonin reuptake inhibitor, DDD defined daily dose
aRestricted to patients with a diagnosis of depression, or prescription of an antidepressant, in the year prior to cancer diagnosis
bAdjusted for age, deprivation, year of diagnosis, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery, tamoxifen, aromatase inhibitors),
comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease,
peripheral vascular disease, renal disease), hot flushes and pre-diagnosis use of hormone replacement therapy or oral contraceptives
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individual studies have reached inconsistent conclusions
[29, 30, 58]. Our finding of higher HRs among tamoxifen
users is broadly consistent with previous work. However,
the persistence of a substantial, albeit attenuated, associ-
ation among patients who did not receive tamoxifen sug-
gests that other mechanisms could be responsible.
Implications for clinicians and researchers
The cause of higher cancer mortality among SSRI users
remains unclear. We cannot rule out a causal relation-
ship as preclinical studies have demonstrated that SSRIs
increase prolactin levels [17–19], an accepted risk factor
for breast cancer progression [20–22], and facilitate
metastasis [23]. Although others have suggested that
SSRIs could lead to poorer cancer outcomes through
inhibition of the CYP2D6 enzyme among tamoxifen users
[29], this was only partially supported by our study.
However, our study findings must be interpreted with
caution as they are particularly vulnerable to confounding
by indication, meaning that SSRI users had a higher
underlying risk of mortality than the non-users. Depres-
sion, the main indication for SSRIs [14], has been shown
to increase mortality in a meta-analysis of 18 studies of
breast cancer patients [59], while a randomised controlled
trial found reduced breast cancer mortality among
patients assigned to a psychological intervention [60].
Although the mechanism for this association remains
unclear, others have hypothesised that pathophysiological
effects, through neuroendocrine and immunological func-
tions, and a reduction in treatment adherence could play
an important role [61]. Given our findings of similar
Table 3 Sensitivity and subgroup analysis for SSRI use and breast cancer mortality
Non-usersa Users Unadjusted HR
(95% CI)
Adjusted HRb
(95% CI)n Person-years Deathsc n Person-years Deaths
Main analysis 18,885 105,433 2539 4784 20,722 514 1.17 (1.07, 1.29) 1.27 (1.16, 1.40)
Death definition
All-cause 18,885 105,433 4358 4784 20,722 933 1.16 (1.08, 1.25) 1.33 (1.23, 1.43)
Primary or secondary breast cancer cause 18,885 105,433 2965 4784 20,722 593 1.16 (1.06, 1.27) 1.28 (1.17, 1.40)
Exposure definition
Year before diagnosis 21,768 138,969 2810 1901 10,855 243 1.09 (0.96, 1.24) 1.18 (1.03, 1.34)
Year after diagnosis 20,999 113,219 2700 2670 12,935 353 1.11 (1.00, 1.25) 1.23 (1.10, 1.38)
Exposure lag
6 months 18,541 114,762 2455 5128 23,195 598 1.25 (1.14, 1.36) 1.36 (1.24, 1.49)
2 years 19,635 87,457 1912 4034 16,319 360 1.14 (1.02, 1.28) 1.22 (1.09, 1.37)
Prior antidepressant medicationd 1769 9316 258 2019 8861 241 1.11 (0.93, 1.33) 1.21 (1.00, 1.45)
SSRI vs other antidepressant medication 3791 17,390 435 4784 20,722 514 1.02 (0.89, 1.15) 1.06 (0.93, 1.20)
Tamoxifen use
Non-user 11,110 52,864 1674 2790 10,678 341 1.16 (1.03, 1.30) 1.25 (1.11, 1.41)
User 7775 52,569 865 1994 10,044 173 1.13 (0.96, 1.34) 1.36 (1.15, 1.61)
Adherant usere 3612 26,159 489 882 4645 86 1.10 (0.87, 1.38) 1.30 (1.03, 1.65)
Adjustment
Excluding ‘previous hot flush’ diagnosisf 18,885 105,433 2539 4784 20,722 514 1.17 (1.07, 1.29) 1.24 (1.12, 1.36)
CC lifestyleg 12,568 70,673 1561 3290 14,116 327 1.18 (1.05, 1.33) 1.24 (1.10, 1.40)
MI lifestyle 18,885 105,433 2539 4784 20,722 514 1.17 (1.07, 1.29) 1.26 (1.14, 1.38)
CC diagnosish 7388 40,419 813 1863 7980 164 1.13 (0.95, 1.34) 1.14 (0.96, 1.35)
MI diagnosis 18,885 105,433 2539 4784 20,722 514 1.17 (1.07, 1.29) 1.27 (1.14, 1.40)
HR hazard ratio, CI confidence interval, SSRI selective serotonin reuptake inhibitor
aExcept for ‘SSRI vs other anti-hypertensive medication’ where patients who received a different anti-hypertensive medication serve as the reference group
bAdjusted for age, deprivation, year of diagnosis, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery, tamoxifen, aromatase inhibitors),
comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease,
peripheral vascular disease, renal disease), hot flushes and pre-diagnosis use of hormone replacement therapy or oral contraceptives
cDeaths with a primary cause of breast cancer unless otherwise stated
dSSRI users vs non-users, restricted to patients with an antidepressant prescription in the year prior to cancer diagnosis
eDefined as having been prescribed at least 150 defined daily doses of tamoxifen in the first six months after cancer diagnosis
fNot adjusting for a previous hot flush diagnosis
gComplete case (CC), additionally adjusted for smoking, obesity and alcohol consumption
hMultiply imputed (MI), additionally adjusted for stage and grade
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associations in medications which have a weaker effect on
prolactin levels or tamoxifen metabolism, and the substan-
tial attenuation of these associations when restricting our
cohort to patients with more similar diagnoses, it seems
likely that confounding by indication is at least partly
driving our results.
Our novel finding of increased cancer-specific mortality
among long-term SSRI users requires further exploration,
particularly as this association was not attenuated when
restricting to those with prior depression diagnosis. It
remains unclear whether this reflects a true effect of
chronic prolactin overexposure on breast cancer progres-
sion, or, perhaps more likely, if issues with confounding by
indication are exacerbated among patients with long-term
depression.
Conclusions
In this large population-based cohort of patients with
registry-confirmed breast cancer, we found increased
breast cancer mortality among SSRI users. However, this
association was non-specific, and was substantially
attenuated in additional analysis restricted to patients
with more similar diagnoses. Consequently, clinicians
should not be unduly concerned when prescribing SSRIs
to breast cancer patients, but further research is needed
into the effects of long-term SSRI use.
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